Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1069

1.

BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.

Gross AL, Blot WJ, Visvanathan K.

JAMA. 2018 Aug 14;320(6):597-598. doi: 10.1001/jama.2018.8258. No abstract available.

PMID:
30120466
2.

Breast Cancer Genetics and Indications for Prophylactic Mastectomy.

Krontiras H, Farmer M, Whatley J.

Surg Clin North Am. 2018 Aug;98(4):677-685. doi: 10.1016/j.suc.2018.03.004. Epub 2018 May 30. Review.

PMID:
30005767
3.

Predictive value of circulating cell-free DNA in the survival of breast cancer patients: A systemic review and meta-analysis.

Yang J, Cheng L, Zhang J, Chen L, Wang D, Guo X, Ma X.

Medicine (Baltimore). 2018 Jul;97(28):e11417. doi: 10.1097/MD.0000000000011417. Review.

4.

Association of XPA polymorphism with breast cancer risk: A meta-analysis.

Zhang Y, Guo Q, Yin X, Zhu X, Zhao L, Zhang Z, Wei R, Wang B, Li X.

Medicine (Baltimore). 2018 Jun;97(26):e11276. doi: 10.1097/MD.0000000000011276.

5.

Gene expression profiling of breast cancer cell lines treated with proton and electron radiations.

Bravatà V, Minafra L, Cammarata FP, Pisciotta P, Lamia D, Marchese V, Petringa G, Manti L, Cirrone GA, Gilardi MC, Cuttone G, Forte GI, Russo G.

Br J Radiol. 2018 Sep;91(1089):20170934. doi: 10.1259/bjr.20170934. Epub 2018 Jul 5.

PMID:
29888960
6.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

PMID:
29860917
7.

Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment.

Pinker K, Chin J, Melsaether AN, Morris EA, Moy L.

Radiology. 2018 Jun;287(3):732-747. doi: 10.1148/radiol.2018172171. Review.

PMID:
29782246
8.

Association between ERα gene Pvu II polymorphism and breast cancer susceptibility: A meta-analysis.

Zhang ZL, Zhang CZ, Li Y, Zhao ZH, Yang SE.

Medicine (Baltimore). 2018 Apr;97(17):e0317. doi: 10.1097/MD.0000000000010317. Review.

9.

Association of rs2279744 and rs117039649 promoter polymorphism with the risk of gynecological cancer: A meta-analysis of case-control studies.

Zhang J, Zhang Y, Zhang Z.

Medicine (Baltimore). 2018 Jan;97(2):e9554. doi: 10.1097/MD.0000000000009554.

10.

Association between rs11200014, rs2981579, and rs1219648 polymorphism and breast cancer susceptibility: A meta-analysis.

Zhang Y, Lu H, Ji H, Lu L, Liu P, Hong R, Li Y.

Medicine (Baltimore). 2017 Dec;96(50):e9246. doi: 10.1097/MD.0000000000009246.

11.

Signatures of DNA-Repair Deficiencies in Breast Cancer.

Turner NC.

N Engl J Med. 2017 Dec 21;377(25):2490-2492. doi: 10.1056/NEJMcibr1710161. No abstract available.

PMID:
29262283
12.

Comparing Outcomes of Genetic Counseling Options in Breast and Ovarian Cancer: An Integrative Review
.

Fournier DM, Bazzell AF, Dains JE.

Oncol Nurs Forum. 2018 Jan 1;45(1):96-105. doi: 10.1188/18.ONF.96-105. Review.

PMID:
29251290
13.

Genetics and genomics of breast fibroadenomas.

Loke BN, Md Nasir ND, Thike AA, Lee JYH, Lee CS, Teh BT, Tan PH.

J Clin Pathol. 2018 May;71(5):381-387. doi: 10.1136/jclinpath-2017-204838. Epub 2017 Dec 16. Review.

PMID:
29248888
14.

Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual and volumetric analysis.

Lecler A, Dunant A, Delaloge S, Wehrer D, Moussa T, Caron O, Balleyguier C.

Br J Radiol. 2018 Feb;91(1083):20170163. doi: 10.1259/bjr.20170163. Epub 2018 Jan 5.

PMID:
29182397
15.

MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.

Xiao M, Lou C, Xiao H, Yang Y, Cai X, Li C, Jia S, Huang Y.

Br J Surg. 2018 Jan;105(1):75-85. doi: 10.1002/bjs.10646. Epub 2017 Nov 8.

PMID:
29116653
16.

Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China.

Jiang W, Li Y, Ou J, Wang X, Zhang C, Yi L, Xue L, Zhang M.

Medicine (Baltimore). 2017 Oct;96(42):e8155. doi: 10.1097/MD.0000000000008155.

17.

Genomic Assays in Ductal Carcinoma In Situ: Implications for Management Decisions.

Gangi A, Topham A, Lee MC, Sun W, Laronga C.

South Med J. 2017 Oct;110(10):649-653. doi: 10.14423/SMJ.0000000000000712.

PMID:
28973706
18.

Identification and Management of TP53 Gene Carriers Detected Through Multigene Panel Testing.

Pal T, Brzosowicz J, Valladares A, Wiesner GL, Laronga C.

South Med J. 2017 Oct;110(10):643-648. doi: 10.14423/SMJ.0000000000000711.

PMID:
28973705
19.

A single nucleotide polymorphism in codon F31I and V57I of the AURKA gene in invasive ductal breast carcinoma in Middle East.

Golmohammadi R, Namazi MJ, Going JJ, Derakhshan MH.

Medicine (Baltimore). 2017 Sep;96(37):e7933. doi: 10.1097/MD.0000000000007933.

20.

Qualitative Radiogenomics: Association between Oncotype DX Test Recurrence Score and BI-RADS Mammographic and Breast MR Imaging Features.

Woodard GA, Ray KM, Joe BN, Price ER.

Radiology. 2018 Jan;286(1):60-70. doi: 10.1148/radiol.2017162333. Epub 2017 Sep 8.

PMID:
28885890

Supplemental Content

Loading ...
Support Center